BSEBoard Meeting2d ago · 15 Oct 2026, 08:13 pm

Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting scheduled to be held on October 20, 2026, inter alia to consider and approve enabling resolution for raising of funds

Orchid Pharma Ltd · 524372

✦ AI SummaryFundraise

Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 to consider and approve enabling resolution for raising of funds.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On October 20, 2026.

Attachments (1)

📄

444e15e7-2db9-4e67-ac26-20f1cf710ca3.pdf

pdf

Download →
View document text
October 15, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai- 400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Sub: Prior Intimation of Board Meeting scheduled to be held on October 20, 2026 Dear Sir/Madam, With reference to captioned subject and in accordance with Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to intimate that the meeting of Board of Directors of Orchid Pharma Limited (“the Company”) is scheduled to be held on Tuesday, October 20, 2026, to consider and evaluate various options for raising funds by way of issue of equity shares or any other eligible securities or instruments, including fully or partly convertible debentures, or through a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares or other eligible securities, by way of qualified institutions placement/ preferential issue/ private placement, public issue of equity shares and/or debt securities or through any other permissible mode, or any combination thereof, as may be considered appropriate, subject to such statutory and regulatory approvals as may be required, including the approval of the members of the Company, wherever applicable, and such other approvals, permissions and consents as may be necessary You are requested to take the above intimation on record Thanking You, For Orchid Pharma Limited Kapil Dayya Company Secretary & compliance officer Mem No.: F10698